<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
Annual Report Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
For the fiscal year ended June 30, 2000 Commission File Number 0-20348
D & K HEALTHCARE RESOURCES, INC.
(Exact name of registrant as specified in its charter)
Delaware 43-1465483
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
8000 Maryland Avenue, Suite 920, St. Louis, Missouri 63105
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code:(314) 727-3485
Securities registered pursuant to Section 12(b) of the Act: None
Securities registered pursuant Common Stock, par value $.01
to Section 12(g) of the Act: (Title of Class)
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days. Yes X No
----- -----
Indicate by check mark if disclosure of delinquent filers pursuant to
Item 405 of Regulation S-K is not contained herein, and will not be
contained, to the best of registrant's knowledge, in definitive proxy or
information statements incorporated by reference in Part III of this Form
10-K or any amendment to this Form 10-K. /x/
State the aggregate market value of the voting stock held by
non-affiliates of the registrant: approximately $33,691,631 as of September
15, 2000.
Indicate the number of shares outstanding of each of the registrant's
classes of common stock, as of the latest practicable date: As of September
15, 2000, 4,219,631 shares of Common Stock, par value $.01, were outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the following documents are incorporated by reference in
the Part of this report indicated below:
Part II - Registrant's 2000 Annual Report to Stockholders
Part III - Registrant's Proxy Statement for its 2000 Annual Meeting of
Stockholders
1
<PAGE> 2
PART I
Item 1. Business
------ --------
OVERVIEW
The Company is the leading publicly held regional wholesale distributor
of pharmaceutical and related healthcare and beauty aid products in the
United States. It serves retail and institutional customers in 24 states
primarily in the Midwest and South. The Company also offers a variety of
value-added services to its customers, particularly in the areas of cost
containment and inventory management. The Company had net sales of $1.5
billion in fiscal 2000, of which 37% were to independent pharmacies, 34% were
to retail chains, including national pharmacy chains and the pharmacy
departments of supermarkets and mass merchandisers, and 29% were to
healthcare institutions, including hospitals, alternate site care facilities,
pharmacy benefit management companies and managed care organizations. The
Company operates from highly efficient and cost effective distribution
facilities in Cape Girardeau, Missouri; a new facility in Lexington,
Kentucky; Minneapolis, Minnesota; Aberdeen, South Dakota; and a new
distribution center in Davie, Florida.
On June 1, 1999, the Company acquired 100% of the outstanding stock of
Jewett Drug Company, Inc., a pharmaceutical distribution company based in
Aberdeen, South Dakota that provides comprehensive pharmaceutical
distribution services to customers in the Upper Midwest and Great Plains
region. The aggregate purchase price for this acquisition of $34.3 million
consisted of $21.5 million in cash and $12.8 million (555,556 shares) of the
Company's common stock.
Since its formation in 1987, the Company has expanded the scope and
breadth of its business by consistently providing the highest levels of
service to its customers and suppliers. The Company achieves such high levels
of service by (i) providing its customers with a full continuum of products,
value-added services and support, which enable its customers to compete more
effectively; (ii) focusing on flexibility, which allows the Company to
respond quickly to change and to customize systems to meet its customers' and
suppliers' requirements; (iii) strategically locating the Company's
distribution centers and satellite transfer depots throughout the Midwest and
the South, which enables the Company to ship products to and service its
customers promptly and efficiently; and (iv) attracting and motivating
experienced and entrepreneurial management personnel, who continually seek to
improve and expand the Company's business.
The management of the Company is focused on continuing its growth through
means that stress: (i) aggressive growth of profitable sales to existing and
new customers; (ii) use of practical cutting-edge technology leading to
increased market share for customers and suppliers; and (iii) empowering its
employees to share innovative ideas with customers and suppliers.
The Company believes that its regional-market focus and high level of
customer service provide it with competitive advantages and position it to
benefit from trends impacting the industry. Management believes that the
increasing size of the wholesale pharmaceutical industry's larger national
participants hampers the ability of these companies to deliver customized
services to most of their customers. The Company has successfully
differentiated itself from its national competitors through its ability to
provide flexible and customized services to its targeted customer segments.
The Company has demonstrated its ability to work with customers to eliminate
inefficiency from the supply chain. In addition, healthcare providers' need
for value-added services which help contain costs and effectively manage
inventory has given the Company the opportunity to capitalize on its cost
competitiveness and advanced systems. The location and quality of the
Company's distribution facilities and satellite transfer depots in the
Midwest and South allow the Company to service its customers' and suppliers'
needs promptly and efficiently. The Company has capitalized on the increased
demand for alternate care providers through its investment in Pharmaceutical
Buyers, Inc. ("PBI") in fiscal 1996. PBI is one of the nation's leading
alternate site group purchasing organizations, and the Company's investment
in PBI provides it with access to a higher margin business segment and
insight into alternate site distribution.
The wholesale pharmaceutical distribution industry has experienced rapid
sales growth over the past 14 years, increasing from approximately $14.0
billion in sales in 1985 to more than $94.8 billion in 1999. The Company
believes that there are several major trends currently affecting the
industry, including: (i) continued consolidation of national and regional
wholesale drug distribution companies; (ii) an increasing emphasis on
value-added services that lower healthcare providers' administrative and
other costs associated with medical supply management; (iii) the growing
importance of an efficient
2
<PAGE> 3
distribution model as customers become more cost conscious; (iv) a shift in the
delivery of healthcare services from acute care settings to alternate sites,
including physician offices and extended care facilities, (v) the aging
population; (vi) the increase in research and development spending by
pharmaceutical manufacturers; and (vii) an increase in direct-to-consumer
advertising are all positively impacting pharmaceutical demand. In addition,
there has been much discussion regarding federal legislative proposals that
would offer outpatient prescription drug benefits to senior citizens under
Medicare or other programs. It is impossible to determine the outcome of these
proposals and what impact they would have on the wholesale drug industry.
PRODUCTS, SERVICES AND VALUE ADDED MARKETING SYSTEMS
The Company's product line consists of more than 25,000 SKUs (stock
keeping units), including branded pharmaceuticals, multi-source generics,
private label products, repackaged pharmaceutical products and over-the-
counter health and beauty aids. The Company sells branded pharmaceuticals
(approximately 87% of net sales in fiscal 2000), generic pharmaceuticals
(approximately 7% of net sales in fiscal 2000) and over-the-counter health
and beauty aids (approximately 6% of net sales in fiscal 2000). In addition,
through its Tykon, Inc. subsidiary (acquired September 1998), the Company
develops and markets a proprietary PC based order entry/order confirmation
system to the drug distribution industry.
During fiscal 2000, the Company formed an alliance with
CornerDrugstore.com, an internet service company that allows pharmacies to
offer their customers online information and ordering capabilities, while
keeping sales in their respective stores. A pharmacy that subscribes to
CornerDrugstore.com can offer consumers a full menu of services over the
internet, including electronic ordering of prescriptions and over-the-counter
products, drug interaction checks, disease information, e-mail refill
reminders and internet links to other local healthcare resources. The
Company will supply the pharmacy with replacement inventory for purchases
made through this service and can also offer the pharmacy the ability to
offer a wider range of products to the consumer without having to keep a
large stock on hand. The Company has also made a minor investment in
CornerDrugstore.com.
The Company strives to offer services that enhance the operating
efficiencies of its customers and assist them in competing effectively.
Principal elements in the Company's service offerings to its customers
include: (i) RESOURCE(SM), a proprietary PC based order entry/order
confirmation system that completely automates all order creation,
transmission and confirmation operations; (ii) PARTNERS(SM), a fully automated
and customizable replenishment software system which helps pharmacies more
efficiently coordinate product supply and demand; (iii) RESOURCE HQ(SM), a
contract management and reporting software system designed for group
purchasing and managed care organizations, and retail chains which automates
functions relating to corporate and group contracts; and (iv) SCRIPTMASTER(R),
a pharmacy management software system that provides prescription management
functions, drug and allergy checks, instantaneous connections to hundreds of
third party insurance plans, "just in time" inventory management, automated
accounts receivable, quick pay program monitoring and central office
functions.
The Company offers a broad range of merchandising and marketing services
to its independent pharmacy customers under its MedPlus(R) identity program.
Under this program, the Company plans and coordinates cooperative advertising
programs and provides for the availability of various promotional products,
including a single-source supply for generics at highly competitive prices
from leading pharmaceutical manufacturers. The Company also offers new
product introduction programs, point-of-sale materials, calendars, blood
pressure testing units, automatic new product distribution, rack jobbing,
store fixturing and retail employee training programs. Other services
offered to independent pharmacies under MedPlus(R) include: retail
merchandising, inventory management systems, electronic order entry,
planogramming, shelf labels and price stickers, private label products,
monthly feature promotions, home healthcare marketing programs, store layout
assistance, business management reports, pharmacy computer systems and
monthly catalogs.
CUSTOMERS AND MARKETS
The Company's diverse customer base consists of independent pharmacies,
retail chains and healthcare institutions. Independent pharmacies generally
are community-based pharmacies, which the Company believes benefit the most
from the Company's sales and value added services. Retail chains, a fast
growing segment of the market, include national pharmacy chains and the
pharmacy departments of supermarkets and mass merchandisers. Healthcare
institutions, which currently
3
<PAGE> 4
comprise the largest segment of the market, consist of hospitals, nursing
homes, clinics and other alternate site care facilities, home health agencies,
HMOs and pharmacy benefit management companies.
The number of independent pharmacies has stabilized since the drop
experienced in 1997. In addition, the Company has worked with entrepreneurs
to open new independent community pharmacies. This could present additional
opportunities as the Company is well positioned to respond to the needs of
new pharmacies requiring a flexible, innovative trading partner.
The Company believes that diversifying its sales across the various
market segments enables it to capture greater market share in the geographic
areas it serves and better serve the faster growing segments of the
healthcare markets. The following table sets forth the Company's sales mix by
customer segment:
<TABLE>
<CAPTION>
NET SALES
---------------------------------------------------------------------------------
Fiscal Years Ended
---------------------------------------------------------------------------------
June 30, 1998 June 30, 1999 June 30, 2000
---------------------- -------------------- ----------------------
Amount Percent Amount Percent Amount Percent
-------- ------- -------- ------- --------- -------
<S> <C> <C> <C> <C> <C> <C>
Independent Pharmacies $300,607 49.1% $382,607 46.9% $ 537,890 36.9%
Retail Chains 131,233 21.4 213,779 26.2 500,662 34.3
Healthcare Institutions 179,658 29.3 216,901 26.6 416,869 28.6
Other 929 0.2 2,032 0.3 2,626 0.2
-------- ----- -------- ----- ---------- -----
$612,427 100.0% $815,319 100.0% $1,458,047 100.0%
======== ===== ======== ===== ========== =====
</TABLE>
The Company's senior management is actively involved in identifying and
developing opportunities to expand the Company's business with customers in
each of these market segments, including the preparation of proposals which
highlight customer benefits of the Company's cost competitiveness, advanced
systems and value added services. During fiscal 1998, fiscal 1999 and fiscal
2000, the Company's 10 largest customers accounted for approximately 37.1%,
52.8% and 55.1%, respectively, of the Company's net sales. The Company's
largest customer during fiscal 2000 was Tel-Drug which accounted for
approximately 18% of the Company's net sales. The Company's largest customer
during fiscal 1999 and 1998 was Anthem Prescription Management, Inc. which
accounted for approximately 12% and 13% of the Company's net sales during
those periods, respectively.
SALES AND MARKETING
The Company employs sales representatives and customer service
representatives at each of its distribution centers. In addition to base
salary, the Company's sales personnel receive incentive compensation based
upon increases in the Company's market share and market penetration. D&K's
corporate vice presidents of business development work closely with each
business unit to develop sales goals. The Company's sales program includes
regular training to improve customer service and to provide its sales and
customer service representatives with the skills and resources necessary to
increase business with existing customers and establish new customer
relationships. The Company also maintains a telephone service department
staffed with trained personnel who work with customers to answer questions
and solve problems.
The Company's marketing efforts are focused on developing new primary
relationships with its customers. The Company emphasizes frequent personal
interaction of its sales force with customers so that the customer comes to
rely on the Company's dependability, responsiveness, accuracy of order
filling and breadth of product line. Retail customers also rely on the
Company's sales force for consulting services on advertising, merchandising,
stocking and inventory management.
The Company believes that its customer service department is a key
element in its marketing program which differentiates it from its national
competitors. The decentralized customer service staff emphasizes rapid
response to customer inquiries and efficient order placement.
4
<PAGE> 5
OPERATIONS
The Company is structured as an organization of locally managed drug
wholesale distribution centers. Each distribution center has an executive,
sales and operations staff with management compensation at each center
determined by its operating results. These operations utilize the Company's
corporate staff for procurement, marketing, financial, legal and executive
management resources and corporate coordination of assets and working capital
management. The Company's decentralized sales and distribution network,
combined with its centralized procurement and corporate support staff
structure, enable the Company to provide high levels of specialized customer
service while minimizing administrative expenses and maximizing volume
discounts for product purchases.
The Company's distribution centers maintain computer systems and
sophisticated materials handling equipment for receiving, storing and
distributing large quantities and varieties of products. The Company
continuously seeks to improve its warehouse automation technologies to
maximize operational efficiencies on a cost-effective basis. The Company
developed state-of-the-art radio frequency (RF) and receiving procedures and
barcoding and scanning technologies at one of its distribution centers which
significantly improved accuracy, efficiency and productivity at that center.
The Company subsequently exported this technology to its other distribution
centers and has developed RF order verification, vendor returns and customer
returns systems.
The Company receives virtually 100% of its orders electronically and,
upon receipt of the customer's order at a distribution center, the Company's
warehouse-management system produces a "picking document" containing product
selection, loading and truck routing information. The system also provides
customized price information (geared to local market as determined by the
customer) or individual package price stickers to accompany each shipment to
facilitate the customer's pricing of the items. Virtually all items ordered
from the Company's distribution centers are available and shipped by the
Company within 24 hours after the orders are placed by customers. Orders are
delivered to customers by the Company's fleet of trucks and vans or by
contract carriers.
PURCHASING AND INVENTORY CONTROL
The Company utilizes sophisticated inventory-control and purchasing
software. The software perpetually tracks the Company's inventory, analyzes
demand history and projects future demand. The Company's system is designed
to enhance profit margins by eliminating the manual ordering process,
allowing for automatic inventory replenishment and identifying inventory
buying opportunities. The system also improves the Company's fill rate and
enhances inventory management and control.
The Company purchases products from approximately 1,000 manufacturers for
the wholesale purchase of pharmaceuticals and other products. The Company
initiates purchase orders with manufacturers through its information systems.
During fiscal 1999 and fiscal 2000, the Company's 10 largest suppliers
accounted for approximately 47% and 52%, respectively, of the Company's
purchases by dollar volume. Historically, the Company has not experienced
difficulty in purchasing desired products from suppliers. The majority of
contracts with suppliers are terminable by either party upon short notice and
without penalty. The Company believes that its relationships with its
suppliers are good.
MANAGEMENT INFORMATION SYSTEMS
Each of the Company's distribution centers operates as a distinct
business with complete systems functionality: order processing, inventory
management, accounts receivable, accounts payable, general ledger, master
file maintenance, external and internal reporting. Historically, the Company
has operated in a distributed data processing environment. Each distribution
center maintained its own AS/400 system and I.S. staff to support that
function. Over the past year, the Company has consolidated all systems into
two major data centers: St. Louis and Cape Girardeau. St. Louis will operate
the production environment while Cape Girardeau will function as a "hot site"
backup to the production environment. Each of the divisions is connected to
the central systems by a frame relay network. Each distribution center and
the corporate offices will continue to house a local area network (LAN) and
multiple PCs. A high-speed data network connects the Company's computer
systems and information is transmitted between locations on a regular basis.
5
<PAGE> 6
In March 2000, the Company selected the JD Edwards OneWorld product as
its new Enterprise Resource Planning (ERP) package. The OneWorld product is
a complete system that integrates sales order management, inventory
management, transportation management, customer service, accounts payable,
accounts receivable, general ledger and financial reporting. The new system
will provide the Company with improved financial reporting systems and
enhanced e-business capabilities. Implementation began in July 2000.
COMPETITION
The wholesale distribution of pharmaceuticals, health and beauty aids,
and other healthcare products is highly competitive, with national and
regional distributors competing primarily on the basis of service and price.
Other competitive factors include delivery service, credit terms, breadth of
product line, customer support, merchandising and marketing programs. The
Company competes with large, national distributors such as McKesson HBOC,
Inc., Bergen Brunswig Corporation, Cardinal Health, Inc., Bindley-Western
Industries, Inc. and AmeriSource Health Corporation, as well as with local
and regional wholesalers, manufacturers and generic pharmaceutical
telemarketers and specialty distributors. The Company also competes with
other wholesale distributors for purchases of products and financial support
in the form of trade credit from manufacturers. Certain of the Company's
competitors have significantly greater financial and marketing resources than
the Company.
EMPLOYEES
As of August 31, 2000, the Company employed 354 persons, 313 of whom were
full-time employees. Approximately 25 of the Company's employees at its
Minneapolis, Minnesota distribution center are covered by a collective
bargaining agreement with the Miscellaneous Drivers, Helpers and
Warehousemen's Union, Local 638, which expires in March 2003. Approximately
18 of the Company's employees at its Jewett Drug Co. subsidiary are covered
by a collective bargaining agreement with the General Drivers and Helpers
Union Local 749, affiliated with the International Brotherhood of Teamsters,
which expires February 29, 2004. In June 2000, the National Labor Relations
Board certified the United Steelworkers of America as the collective
bargaining representative for approximately 39 of the Company's employees at
its Cape Girardeau, Missouri distribution center. The Company believes that
its employee relations are good.
FORWARD-LOOKING STATEMENTS
Certain statements in this document regarding future events, prospects,
projections or financial performance are forward looking statements. Such
forward looking statements are made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995 and may also be
identified by words such as "anticipates," "believes," "estimates,"
"expects," "intends" and similar expressions. Such statements are subject to
risks and uncertainties that could cause actual results to differ materially
from those described in or suggested by such forward looking statements.
These risks and uncertainties include the Company's ability to compete in a
competitive industry, with many competitors having substantially greater
resources than the Company and the Company's customers generally having the
right to terminate their contracts with the Company or reduce purchasing
levels on relatively short notice without penalty, the Company's ability to
maintain or improve its operating margin with the industry's competitive
pricing pressures, the changing business and regulatory environment,
including possible changes in reimbursement for healthcare products and in
manufacturers' pricing or distribution policies, the continued availability
of investment buying opportunities, the loss of one or more key suppliers for
which alternative sources may not be available, and the ability to integrate
recently acquired businesses. Readers are cautioned not to place undue
reliance on these forward-looking statements, which reflect the Company's
views as of the date hereof. The Company undertakes no obligation to publicly
update or revise any forward-looking statements.
Item 2. Properties
------ ----------
The Company conducts its business from a total of nine office, warehouse
and satellite depot facilities. The Company's primary operating facilities
include:
6
<PAGE> 7
<TABLE>
<CAPTION>
LOCATION DESCRIPTION SQUARE FOOTAGE
----------------------------- ------------------------------- --------------
<S> <C> <C>
Cape Girardeau, Missouri <F1> Distribution and administration 66,000
Lexington, Kentucky <F1> Distribution and administration 61,900
Minneapolis, Minnesota <F2> Distribution and administration 63,000
Aberdeen, South Dakota <F1> Distribution and administration 40,000
Davie, Florida <F1> Distribution and administration 10,700
St. Louis, Missouri <F1> Corporate Offices 11,500
<FN>
<F1> Leased
<F2> Owned
</TABLE>
The Company also maintains warehouse and satellite depot facilities in
Missouri, Tennessee, and Kentucky that enable it to efficiently distribute
product on a timely basis.
The Company believes its facilities are adequate to support its present
business plans.
Item 3. Legal Proceedings
------ -----------------
No material legal proceedings are pending against the Company.
Item 4. Submission of Matters to a Vote of Security Holders
------- ---------------------------------------------------
The Company did not submit any matters to a vote of its security holders
during the quarter ended June 30, 2000.
Item 4A. Executive Officers of the Registrant
------- ------------------------------------
The name, age and position of each of the executive officers of the
Company are set forth below.
J. Hord Armstrong, III, 59, has served as the Chairman of the Board,
Chief Executive Officer and Treasurer and as a director of the Company since
December 1987. Prior to joining the Company, Mr. Armstrong served as Vice
President and Chief Financial Officer of Arch Mineral Corporation, a coal
mining and sales corporation, from 1981 to 1987 and as its Treasurer from
1978 to 1981. Mr. Armstrong serves as a Trustee of the St. Louis College of
Pharmacy and as a member of the Board of Directors of Jones Pharma, Inc.
Martin D. Wilson, 39, has served as President and Chief Operating Officer
of the Company since January 1996, as Secretary since August 1993 and as a
director since 1997. Mr. Wilson previously served as Executive Vice
President, Finance and Administration of the Company from May 1995 to January
1996, as Vice President, Finance and Administration of the Company from April
1991 to May 1995 and as Controller of the Company from March 1988 to April
1991. Prior to joining the Company, Mr. Wilson, a certified public
accountant, was associated with KPMG Peat Marwick, a public accounting firm.
Thomas S. Hilton, 48, has served as Senior Vice President and Chief
Financial Officer of the Company since January 1999. Between May 1980 and
June 1998, Mr. Hilton was employed by the Peabody Group serving in a variety
of management positions including Vice President and Treasurer from March
1993 to May 1995 and as Vice President and Chief Financial Officer from May
1995 to June 1998.
Leonard R. Benjamin, 50, has served as Vice President, General Counsel
and Secretary of the Company since April 1999. Between January 1999 and
April 1999, Mr. Benjamin was Assistant General Counsel of Innovex
Corporation, a provider of sales forces to the pharmaceutical industry.
Between October 1998 and January 1999, Mr. Benjamin was counsel to KWS&P/SFA
Inc., a software provider to the pharmaceutical industry. Between April 1994
and July 1998, Mr. Benjamin was employed by Walsh International Inc., a
software provider to the pharmaceutical industry, initially as Associate
General Counsel and then as Vice President, General Counsel and Secretary.
7
<PAGE> 8
Brian G. Landry, 44, has served as Vice President and Chief Information
Officer since April 2000. Mr. Landry previously served as Vice President,
I.S. product management from April 1999 to April 2000 and as Vice President
and General Manager of the Minneapolis distribution center from November 1996
to April 1999. From October 1992 to October 1996, Mr. Landry was employed by
Cardinal Health as a general manager of a distribution center.
James D. Largent, 62, has served as Vice President - Business Development
of the Company since July 1999. Mr. Largent joined Delta Wholesale Drug,
Inc. in March 1968, which was acquired by the Company in December 1987. Mr.
Largent has served in a variety of management positions with the Company
including Vice President and General Manager of the Cape Girardeau
distribution center from May 1995 to July 1999.
Lewis E. Mead, 50, has served as Vice President - Business Development of
the Company since July 1999. Mr. Mead previously served as Vice President
and General Manager of the Lexington distribution center from February 1996
to July 1999. From May 1992 to February 1996, Mr. Mead served in various
sales management positions with FoxMeyer Drug Company, which was a national
wholesale drug distributor.
James A. Cordes, 52, has served as Vice President - Professional Trade
Services of the Company since January 2000. Between January 1991 and
December 1999, Mr. Cordes was Director of Professional Services for Schnuck
Markets, Inc., a regional supermarket chain.
8
<PAGE> 9
PART II
Item 5. Market for Registrant's Common Equity and Related Stockholder Matters
------ ---------------------------------------------------------------------
The information set forth under the caption "Price Range Per Common
Share" on inside back cover of the registrant's 2000 Annual Report to
Stockholders is incorporated herein by this reference.
Item 6. Selected Financial Data
------ -----------------------
The information set forth under the caption "Financial Highlights" on
page 1 of the registrant's 2000 Annual Report to Stockholders is incorporated
herein by this reference.
Item 7. Management's Discussion and Analysis of Financial Condition
------ -----------------------------------------------------------
and Results of Operations
-------------------------
RESULTS OF OPERATIONS
The table below sets forth certain statement of operations data for the
last three fiscal years expressed as a percentage of net sales and in
comparison with the prior fiscal year. Unless otherwise indicated, for
purposes of this discussion, all references to "2000," "1999," and "1998"
shall mean the Company's fiscal years ended June 30, 2000, June 30, 1999, and
June 30, 1998, respectively. The Company has given retroactive effect to the
change in accounting for determining the cost of its inventory from the
last-in, first-out method to the first-in, first-out method. Accordingly,
previously reported figures have been restated to account for this change.
See Note 3 of "Notes to Consolidated Financial Statements."
<TABLE>
<CAPTION>
-------------------------------------- ---------------------------
Percentage Change from
Percentage of Net Sales Prior Year
-------------------------------------- ---------------------------
2000 1999 1998 1999-2000 1998-99
-------- -------- -------- ------------- -----------
<S> <C> <C> <C> <C> <C>
Net sales 100.00% 100.00% 100.00% 78.8% 33.1%
Gross profit 3.87% 5.09% 5.01% 35.8% 35.5%
Total operating expenses (2.34%) (3.27%) (3.41%) 27.8% 27.8%
-------- -------- --------
Income from operations 1.53% 1.82% 1.60% 50.2% 51.9%
Interest expense, net (0.66%) (0.57%) (0.62%) 107.9% 21.8%
Other income, net 0.05% 0.05% 0.08% 70.8% (18.7%)
Income tax provision (0.36%) (0.49%) (0.42%) 29.6% 57.3%
-------- -------- --------
Net income 0.56% 0.81% 0.64% 23.8% 68.1%
======== ======== ========
</TABLE>
FISCAL YEAR ENDED JUNE 30, 2000, COMPARED WITH THE FISCAL YEAR ENDED JUNE 30,
1999
NET SALES. Net sales increased $642.7 million, or 78.8%, for the fiscal year
ended June 30, 2000, compared with the fiscal year ended June 30, 1999. Sales
were significantly impacted by the inclusion of the Company's acquisition of
a drug wholesaler in June 1999. Institutional sales increased by $200.0
million, or 92.2% compared with fiscal 1999, due to sales to a prescription
benefit management company that became a customer as a result of that
acquisition. Chain store sales increased by $286.9 million, or 134.2%, from
higher sales to existing and new chain store customers resulting from a
focused marketing effort on this trade class. Independent pharmacy sales
increased by $155.2 million, or 40.6% from higher sales to existing customers
and new customers, including those obtained in the June 1999 acquisition.
The remaining $0.6 million sales increase was primarily from software sales
by Tykon, Inc. acquired in September 1998. The supply contracts with two
customers (including the Company's largest customer), representing
approximately 23% of fiscal 2000 sales, were terminated in the fourth quarter
of fiscal 2000. As a result, the Company anticipates that institutional
sales will decrease in fiscal 2001. In addition, during fiscal 2000, the
Company made $46.8 million in "dock-to-dock" sales, which are not included in
net sales
9
<PAGE> 10
due to the Company's accounting policy of recording only the commission on such
transactions as a reduction of cost of goods sold. There were $189.0 million of
dock-to-dock sales in fiscal 1999. Dock-to-dock sales represent bulk sales of
pharmaceuticals to self-warehousing retail chains for which the Company acts
only as an intermediary in the order and subsequent delivery of products to the
customers' warehouses. The commission on dock-to-dock sales is typically lower
than the gross profit realized on sales of products from inventory.
GROSS PROFIT. Gross profit increased 35.8%, to $56.4 million in fiscal 2000
compared with fiscal 1999 driven primarily by higher sales. As a percentage
of net sales, gross margin decreased from 5.09% to 3.87% in fiscal 2000
compared with fiscal 1999. The decrease in gross margin percentage was mainly
due to a shift in customer mix as a result of the June 1999 acquisition
partially offset by higher sales of more profitable generic pharmaceutical
products and sales of inventory acquired through advantageous purchasing.
OPERATING EXPENSES. Total operating expenses increased $7.4 million, or
27.8%, to $34.1 million in fiscal 2000, compared with fiscal 1999. As a
percentage of net sales, total operating expenses decreased from 3.27% to
2.34% in fiscal 2000 compared with fiscal 1999. The increase in operating
expenses in fiscal 2000 resulted primarily from the Company's acquisition in
June 1999. The decrease in operating expense percentage for the year is due
mainly to the increase in sales that generated a lower expense to sales
ratio.
NET INTEREST EXPENSE. Net interest expense increased $5.0 million, or 107.9%,
in fiscal 2000, compared with fiscal 1999. As a percentage of net sales, net
interest expense increased from 0.57% to 0.66% in fiscal 2000 compared with
fiscal 1999. The increase in net interest expense was primarily the result of
higher average outstanding borrowings in support of the Company's growth and
by higher weighted average interest rates. Weighted average interest rates
increased 105 basis points to 7.31% for the year primarily due to market
conditions during fiscal 2000.
OTHER INCOME, NET. Other income, net increased from $431,000 to $736,000 in
fiscal 2000 compared with fiscal 1999. The increase was primarily due to
higher recorded earnings from the Company's equity interest in the net income
of PBI during fiscal 2000, which totaled $634,000, compared with $332,000 in
fiscal 1999.
INCOME TAX PROVISION. The Company's effective income tax rates of 38.8% in
fiscal 2000 and 37.7% in fiscal 1999 differed from the statutory blended
federal and state effective rates primarily due to the impact of the
amortization of intangible assets that were not deductible for income tax
purposes, partially offset by the Company's equity in the net income of PBI,
a portion of which is excludable from taxable income.
FISCAL YEAR ENDED JUNE 30, 1999, COMPARED WITH THE FISCAL YEAR ENDED JUNE 30,
1998
NET SALES. Net sales increased $202.9 million, or 33.1%, for the fiscal year
ended June 30, 1999, compared with the fiscal year ended June 30, 1998.
Institutional sales increased by $37.3 million, or 20.7% compared with fiscal
1998, due to increased sales to one prescription benefit management company
(PBM) and sales to another PBM that became a customer as a result of the
Company's acquisition of a drug wholesaler in June 1999. Chain store sales
increased by $82.5 million, or 62.9%, from higher sales to existing and new
chain store customers resulting from a focused marketing effort on this trade
class. Independent pharmacy sales increased by $82.0 million, or 27.3% from
higher sales to existing customers and new customers, including those
obtained in the June 1999 acquisition. The remaining $1.1 million sales
increase was primarily from software sales by Tykon, Inc. acquired in
September 1998. In addition, during fiscal 1999, the Company made $189.0
million in "dock-to-dock" sales, which are not included in net sales due to
the Company's accounting policy of recording only the commission on such
transactions as a reduction of cost of goods sold. There were $62.1 million
of dock-to-dock sales in fiscal 1998.
GROSS PROFIT. Gross profit increased 35.5%, to $41.5 million in fiscal 1999
compared with fiscal 1998 driven primarily by higher sales and partially by
improved margins. As a percentage of net sales, gross margin increased from
5.01% to 5.09% in fiscal 1999 compared with fiscal 1998. The increase in
gross margin percentage was mainly due to a shift in customer mix to higher
margin business, higher sales of more profitable generic pharmaceutical
products and sales of inventory acquired through advantageous purchasing.
These benefits were partially offset by higher sales to large customers that
typically generate lower margins.
10
<PAGE> 11
OPERATING EXPENSES. Total operating expenses increased $5.8 million, or
27.8%, to $26.7 million in fiscal 1999, compared with fiscal 1998. As a
percentage of net sales, total operating expenses decreased from 3.41% to
3.27% in fiscal 1999 compared with fiscal 1998. The increase in operating
expenses in fiscal 1999 resulted primarily from incremental warehouse and
distribution costs associated with increased sales activity and higher
personnel costs related to additional managerial positions in several major
functional areas of the Company. The decrease in operating expense
percentage for the year is due mainly to the increase in chain store sales
that typically generate a lower expense to sales ratio than other trade
classes.
NET INTEREST EXPENSE. Net interest expense increased $0.8 million, or 21.8%,
in fiscal 1999, compared with fiscal 1998. As a percentage of net sales, net
interest expense decreased from 0.62% to 0.57% in fiscal 1999 compared with
fiscal 1998. The increase in net interest expense was primarily the result of
higher average outstanding borrowings in support of the Company's growth,
partially offset by lower weighted average interest rates. Weighted average
interest rates decreased 91 basis points to 6.26% for the year primarily due
to the accounts receivable securitization facility finalized in August 1998.
OTHER INCOME, NET. Other income, net decreased from $530,000 to $431,000 in
fiscal 1999 compared with fiscal 1998. The decrease was primarily due to
lower recorded earnings from the Company's equity interest in the net income
of PBI during fiscal 1999, which totaled $332,000, compared with $389,000 in
fiscal 1998.
INCOME TAX PROVISION. The Company's effective income tax rates of 37.7% in
fiscal 1999 and 39.3% in fiscal 1998 differed from the statutory blended
federal and state effective rates primarily due to the impact of the
amortization of intangible assets that were not deductible for income tax
purposes, partially offset by the Company's equity in the net income of PBI,
a portion of which is excludable from taxable income.
LIQUIDITY AND CAPITAL RESOURCES
The Company's working capital requirements are generally met through a
combination of internally generated funds, borrowings under the revolving
line of credit, the accounts receivable securitization facility, and trade
credit from its suppliers. The Company uses the following ratios as key
indicators of its liquidity and working capital management:
<TABLE>
<CAPTION>
June 30, 2000 June 30, 1999
----------------- -----------------
<S> <C> <C>
Working capital (000s) $93,556 $28,525
Current ratio 1.65 to 1 1.19 to 1
</TABLE>
The $65.0 million increase in working capital at June 30, 2000 was due
primarily to the increase in accounts receivable and inventory as a result of
increased sales and the Company's on-going growth requiring additional
investment in inventories.
The Company invested $3.3 million in capital assets in fiscal 2000 and
$879,000 in fiscal 1999. This increase was due in part to the move to a new
facility in Lexington, Kentucky and the initial payments associated with the
new ERP system that the Company is implementing. The Company believes that
continued investment in capital assets is necessary to achieve its goal of
improving operating efficiency and information services capabilities, thereby
improving its productivity and ratio of operating expenses to net sales.
As of June 30, 2000, the revolving line of credit had a maximum borrowing
capacity of $120 million, expiring in August 2001. Prior to December 1999,
the revolving line of credit had maximum borrowing capacity of $95.0 million.
Under the loan agreement, the total amount of loans and letters of credit
outstanding at any time may not exceed the lesser of an amount based on
percentages of eligible inventories (the borrowing base formula), or the
maximum borrowing capacity. In December 1999, an additional seasonal line of
credit was added to this facility increasing the maximum borrowing capacity
to $120 million during a seasonal period. Such seasonal period starts on or
after October 1 but not later than December 1 of each year and continues
until six months after the commencement of such seasonal period, which was
extended through September 30, 2000 for the current fiscal year. Generally,
advances bear interest at the London Interbank Offered Rate (LIBOR) plus
1.75% or at the prime rate (8.43% at June 30, 2000) plus .25% per annum
payable monthly. On May 4, 2000, the Company fixed $20 million of its
revolving line of credit at a nominal rate of 7.30%. At June 30, 2000 and
June 30, 1999, the unused portion of the line of credit amounted to $22.0
million and $55.5 million, respectively. The agreement expires August 7,
2001, and, therefore, the related debt has been classified as long-term. The
revolving line of credit is secured by eligible inventories. The Company is
engaged in discussions to extend the life of the revolving credit arrangement
by one year and expand the borrowing capacity to $130 million year-round.
11
<PAGE> 12
In the first quarter of fiscal 1999, the Company entered into a $45
million accounts receivable purchase facility under an asset securitization
structure (the "Securitization") with its primary lender. In the second
quarter of fiscal 1999, the Securitization was increased to $60 million and
to $75 million in the fourth fiscal quarter of 2000. The Securitization has
an initial term of three years, with annual renewal options, and bears
interest at the LIBOR rate (6.68% at June 30, 2000) plus program and
liquidity fees of 0.71% paid monthly. Under the Securitization, accounts
receivable are sold on a non-recourse basis to a bankruptcy-remote subsidiary
of the Company as security for commercial paper issued by an affiliate of the
lender. Based upon the structure of the arrangement, the subsidiary's assets
and liabilities, consisting of accounts receivable and long-term debt, are
not consolidated with those of the Company. Accordingly, the company's trade
accounts receivable at June 30, 2000 and 1999 are net of $75.0 million and
$35.0 million, respectively, which represent accounts receivable that were
sold under the Securitization.
To hedge its floating rate exposure, the Company has an interest rate
collar agreement, whereby the LIBOR on $10 million of the outstanding
revolving line of credit balance shall not exceed 6.75%. If the LIBOR is
less than 5.25%, then the LIBOR rate on $7.5 million of the outstanding
revolving line of credit balance shall not be less than 5.25%. The Company
has an additional interest rate collar agreement on $40 million of the
outstanding revolving line of credit, whereby the LIBOR shall not exceed
6.85% nor be less than 4.93%. At June 30, 2000, the approximate value of these
instruments was $115,000. Both of these agreements expire in August 2001.
The Company believes that funds available under the line of credit and
the securitization facility, together with internally generated funds, will
be sufficient to meet its capital requirements for the foreseeable future.
On June 1, 1999, the Company consummated the acquisition of 100% of the
outstanding stock of Jewett Drug Co. ("Jewett"). Jewett is a pharmaceutical
distribution company based in Aberdeen, South Dakota, which provides
comprehensive pharmaceutical distribution services to customers in the Upper
Midwest and Great Plains region. The aggregate purchase price for this
acquisition of $34.3 million consisted of $21.5 million in cash and $12.8
million (555,556 shares) of the Company's common stock. Funds for the cash
portion of the purchase price were provided by the Company's revolving loan
facility. The acquisition was accounted for as a purchase. As such, Jewett
results are included in consolidated operating results from the acquisition
date. The acquisition resulted in goodwill of $30.9 million, which is being
amortized over 25 years.
In September 1998, the Company acquired 100% of the stock of Tykon, Inc.,
a wholesale distribution software developer, for cash consideration of $2.0
million. During fiscal 1998, the Company made two acquisitions of
pharmaceutical distribution companies for aggregate consideration of $2.6
million, including cash payments and the issuance of notes payable.
Shareholders' equity increased to $45.3 million at June 30, 1999 from
$40.9 million at June 30, 1998, primarily due to net earnings of $8.2 million
offset by the purchase of $4.6 million of treasury stock.
INFLATION
The Company's financial statements are prepared on the basis of
historical costs and are not intended to reflect changes in the relative
purchasing power of the dollar. Because of the ability to take advantage of
forward purchasing opportunities, the Company believes that its gross profits
generally increase as a result of manufacturers' price increases in the
products it distributes. Gross profits may decline if the rate of price
increases by manufacturers declines.
Generally, price increases are passed through to customers as they are
received by the Company and therefore reduce the negative effect of
inflation. Other non-inventory cost increases, such as payroll, supplies and
services, have been partially offset during the past three years by increased
volume and productivity.
YEAR 2000
The Company has not been adversely affected by any Year 2000 problems as
of the filing date and does not anticipate any such problems in the future.
As of June 30, 2000, the Company had cumulatively spent approximately
$662,000 on its Year 2000 project primarily on remediation and testing the
Company's software products and on contingency planning. No additional
spending is anticipated
EFFECT OF NEW ACCOUNTING STANDARDS
In June, 1998, the Financial Accounting Standards Board issued SFAS No.
133, "Accounting for Derivative Instruments and Hedging Activities," which is
required to be adopted in years beginning after June 15, 2000. Accordingly,
12
<PAGE> 13
the Company adopted the provisions of this statement on July 1, 2000,
resulting in an increase in stockholders' equity of approximately $69,000.
Item 7A. Quantitative and Qualitative Disclosures About Market Risk
------- ----------------------------------------------------------
Not applicable.
Item 8. Financial Statements and Supplementary Data
------ -------------------------------------------
<TABLE>
<CAPTION>
ANNUAL REPORT REFERENCE
---------------------------
<S> <C>
Report of Independent Public Accountants Page 14
Consolidated Balance Sheets at June 30, 2000 and June 30, 1999 Page 15
Consolidated Statements of Operations for the years ended June 30, 2000,
June 30, 1999, and June 30, 1998 Page 16
Consolidated Statements of Stockholders' Equity for the years
Ended June 30, 2000, June 30, 1999, and June 30, 1998 Page 17
Consolidated Statements of Cash Flows for the years ended June 30, 2000,
June 30, 1999, and June 30, 1998 Page 18
Notes to Consolidated Financial Statements Page 19
</TABLE>
13
<PAGE> 14
REPORT OF INDEPENDENT PUBLIC ACCOUNTANTS
To D&K Healthcare Resources, Inc.:
We have audited the accompanying consolidated balance sheets of D&K
Healthcare Resources, Inc. (a Delaware corporation) and subsidiaries as of
June 30, 2000 and 1999, and the related consolidated statements of
operations, stockholders' equity and cash flows for the three fiscal years
then ended. These financial statements are the responsibility of the
Company's management. Our responsibility is to express an opinion on these
financial statements based on our audits.
We conducted our audits in accordance with auditing standards generally
accepted in the United States. Those standards require that we plan and
perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement. An audit includes examining,
on a test basis, evidence supporting the amounts and disclosures in the
financial statements. An audit also includes assessing the accounting
principles used and significant estimates made by management, as well as
evaluating the overall financial statement presentation. We believe that our
audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present
fairly, in all material respects, the financial position of D&K Healthcare
Resources, Inc. and subsidiaries as of June 30, 2000 and 1999, and the
results of their operations and their cash flows for the three fiscal years
then ended, in conformity with accounting principles generally accepted in the
United States.
As explained in Note 3 to the financial statements, the Company has given
retroactive effect to the change in accounting for determining the cost of
its inventory from the last-in, first-out method to the first-in, first-out
method.
Our audit was made for the purpose of forming an opinion on the basic
financial statements taken as a whole. Schedule II is presented for purposes
of complying with the Securities and Exchange Commission's rules and is not
part of the basic financial statements. This schedule has been subjected to
the auditing procedures applied in the audit of the basic financial
statements and, in our opinion, fairly states in all material respects the
financial data required to be set forth therein in relation to the basic
financial statements taken as a whole.
/s/ Arthur Andersen LLP
St. Louis, Missouri
August 9, 2000
14
<PAGE> 15
<TABLE>
<CAPTION>
D&K HEALTHCARE RESOURCES, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)
------------------------------------------------------------------------------------------------------------------
JUNE 30, 2000 JUNE 30, 1999
------------------------------------------------------------------------------------------------------------------
<S> <C> <C>
ASSETS
Current Assets
Cash (including restricted cash) $ 3,661 $ 708
Receivables, net of allowance for doubtful accounts of
$1,411 and $1,142, respectively 29,923 14,889
Inventories 202,467 165,628
Deferred income taxes 441 --
Prepaid expenses and other current assets 1,002 599
------------------------------------
Total current assets 237,494 181,824
Property and Equipment, net of accumulated depreciation
and amortization 8,184 6,205
Investment in Affiliates 5,199 4,111
Other Assets 1,026 1,041
Intangible assets, net of accumulated amortization 42,516 43,809
------------------------------------
Total assets $294,419 $236,990
====================================
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities
Current maturities of long-term debt $ 305 $ 403
Accounts payable 134,834 142,360
Accrued expenses 8,799 8,251
Deferred income taxes -- 2,285
------------------------------------
Total current liabilities 143,938 153,299
Long-term Liabilities 700 482
Deferred Income Taxes 4,869 1,873
Long-term Debt 99,647 40,449
------------------------------------
Total liabilities 249,154 196,103
Stockholders' Equity
Preferred stock -- --
Common stock 42 44
Paid-in capital 30,335 29,555
Retained earnings 20,431 12,232
Less treasury stock (5,543) (944)
------------------------------------
Total stockholders' equity 45,265 40,887
------------------------------------
Total liabilities and stockholders' equity $294,419 $236,990
====================================
Preferred stock has no par value; 1 million shares are authorized. At June 30, 2000 and 1999, no shares were issued or
outstanding.
Common stock has a par value of $.01 per share; 10 million shares are authorized; 4,484,329 and 4,413,781 shares were issued at
June 30, 2000 and 1999, respectively. At June 30, 2000, 4,187,929 shares were outstanding and 296,400 shares were held in
treasury. At June 30, 1999, 4,373,881 shares were outstanding and 39,900 shares were held in treasury.
The accompanying notes are an integral part of these statements.
</TABLE>
15
<PAGE> 16
<TABLE>
D&K HEALTHCARE RESOURCES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
<CAPTION>
(in thousands, except per share data) For the Years Ended
----------------------------------------------------------------------------------------------------
JUNE 30, 2000 JUNE 30, 1999 JUNE 30, 1998
----------------------------------------------------------------------------------------------------
<S> <C> <C> <C>
Net Sales $1,458,047 $815,319 $612,427
Cost of Sales 1,401,625 773,783 581,773
-------------------------------------------------------
Gross profit 56,422 41,536 30,654
Depreciation and Amortization 3,118 1,647 1,468
Operating Expenses 31,005 25,047 19,416
-------------------------------------------------------
Income from operations 22,299 14,842 9,770
-------------------------------------------------------
Other Income (Expense)
Interest expense (10,643) (5,266) (4,080)
Interest income 1,007 630 273
Equity in net income of PBI 634 332 389
Other, net 102 99 141
-------------------------------------------------------
(8,900) (4,205) (3,277)
-------------------------------------------------------
Income before income
tax provision 13,399 10,637 6,493
-------------------------------------------------------
Income Tax Provision 5,200 4,012 2,551
-------------------------------------------------------
Net income $ 8,199 $ 6,625 $ 3,942
-------------------------------------------------------
Basic Earnings Per Share $ 1.93 $ 1.72 $ 1.18
=======================================================
Diluted Earnings Per Share $ 1.84 $ 1.58 $ 1.07
=======================================================
The accompanying notes are an integral part of these statements.
</TABLE>
16
<PAGE> 17
<TABLE>
D&K HEALTHCARE RESOURCES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
<CAPTION>
(in thousands)
---------------------------------------------------------------------------------------------------------------------
COMMON PAID-IN RETAINED TREASURY
STOCK CAPITAL EARNINGS STOCK TOTAL
---------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C>
BALANCE AT JUNE 30, 1997, AS ORIGINALLY REPORTED $ 30 $11,835 $(2,487) $ -- $ 9,378
Adjustment for change in valuation of
inventory (see Note 3) -- -- 4,152 -- 4,152
---------------------------------------------------------------
BALANCE AT JUNE 30, 1997 30 11,835 1,665 -- 13,530
Common stock issued upon debt conversions 6 2,744 -- -- 2,750
Stock options and warrants exercised,
including tax benefit 1 496 -- -- 497
Net Income -- -- 3,942 -- 3,942
---------------------------------------------------------------
BALANCE AT JUNE 30, 1998 37 15,075 5,607 -- 20,719
Common stock issued 6 12,843 -- -- 12,849
Stock options exercised, including tax benefit 1 1,637 -- -- 1,638
Treasury stock acquired -- -- -- (944) (944)
Net Income -- -- 6,625 -- 6,625
---------------------------------------------------------------
BALANCE AT JUNE 30, 1999 44 29,555 12,232 (944) 40,887
Stock options exercised, including tax benefit 1 780 -- -- 781
Treasury stock acquired (3) -- -- (4,599) (4,602)
Net Income -- -- 8,199 8,199
---------------------------------------------------------------
BALANCE AT JUNE 30, 2000 $ 42 $30,335 $20,431 $(5,543) $45,265
---------------------------------------------------------------
The accompanying notes are an integral part of these statements.
</TABLE>
17
<PAGE> 18
<TABLE>
D&K HEALTHCARE RESOURCES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
<CAPTION>
(in thousands) For the Years Ended
----------------------------------------------------------------------------------------------------------------------
JUNE 30, 2000 JUNE 30, 1999 JUNE 30, 1998
----------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C>
CASH FLOWS FROM OPERATING ACTIVITIES
Net income $ 8,199 $ 6,625 $ 3,942
Adjustments to reconcile net income to net cash
flows from operating activities --
Depreciation and amortization 3,118 1,647 1,468
Amortization of debt issuance costs 375 188 59
Gain from sale of assets (16) (9) (32)
Equity in net income of PBI (634) (332) (389)
Deferred income taxes 270 492 1,241
(Increase) decrease in receivables, net (15,034) 41,182 (16,500)
Increase in inventories (36,839) (42,437) (48,791)
(Increase) decrease in prepaid expenses and other
current assets (403) 242 633
Increase (decrease) in accounts payable (7,526) 39,297 31,491
Increase (decrease) in accrued expenses 548 (7,729) 312
Other, net (427) (157) 432
---------------------------------------------------
Net cash flows from operating activities (48,369) 39,009 (26,134)
---------------------------------------------------
CASH FLOWS FROM INVESTING ACTIVITIES
Payments for acquisitions, net of cash acquired -- (13,961) (1,256)
Investment in affiliates (804) -- --
Cash dividend from PBI 350 350 350
Purchases of property and equipment (3,270) (879) (863)
Proceeds from sale of assets 16 752 32
---------------------------------------------------
Net cash flows from investing activities (3,708) (13,738) (1,737)
---------------------------------------------------
CASH FLOWS FROM FINANCING ACTIVITIES
Borrowings under revolving line of credit 538,303 487,844 429,431
Repayments under revolving line of credit (479,767) (513,714) (397,997)
Proceeds from equipment loan 965 -- --
Payments of long-term debt (283) (1,973) (1,571)
Payments of capital lease obligations (118) (9) --
Proceeds from exercise of stock options and warrants 814 822 413
Purchase of treasury stock (4,602) (944) --
Payments of deferred debt costs (282) (640) --
---------------------------------------------------
Net cash flows from financing activities 55,030 (28,614) 30,276
---------------------------------------------------
Increase (decrease) in cash 2,953 (3,343) 2,405
Cash, beginning of period 708 4,051 1,646
---------------------------------------------------
Cash, end of period $ 3,661 $ 708 $ 4,051
---------------------------------------------------
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid during the period for --
Interest $ 10,499 $ 4,927 $ 3,601
Income taxes, net $ 3,698 $ 2,755 $ 1,151
The accompanying notes are an integral part of these statements.
</TABLE>
18
<PAGE> 19
D&K HEALTHCARE RESOURCES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:
The consolidated financial statements include the accounts of all divisions
and wholly owned subsidiaries of D&K Healthcare Resources, Inc. (the Company).
All significant intercompany accounts and transactions are eliminated.
Fiscal Year
The Company's fiscal year end is June 30. References to years relate to
fiscal years rather than calendar years unless otherwise stated.
Concentration of Credit Risk
The Company is a full-service, regional wholesale drug distributor. From
facilities in Missouri, Kentucky, Minnesota, South Dakota and Florida, the
Company distributes a broad range of pharmaceutical products, health and
beauty aids and related products to its customers in more than 24 states.
The Company focuses primarily on a target market sector, which includes
independent retail, institutional, franchise, chain store, and alternate site
pharmacies in the Midwest and South.
In 2000 sales to one customer represented approximately 18% of total net
sales. In 1999 and 1998, sales to a different customer represented
approximately 12% and 13% of total net sales, respectively. The supply
contracts with two customers (including the Company's largest customer),
representing approximately 23% of fiscal 2000 sales, were terminated in the
fourth quarter of fiscal 2000.
Use of Estimates
The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the
reporting period. Actual results could differ from those estimates.
Restricted Cash
Restricted cash of $3.7 million and $0.7 million, respectively, at June
30, 2000 and June 30, 1999, represents cash receipts from customers that must
be used to reduce borrowings under the revolving line of credit and are
included in cash.
Revenue Recognition
Revenue is recognized when products are shipped or services are provided
to customers. During 2000, 1999 and 1998, the Company had $46.8 million,
$189.0 million, and $62.1 million, respectively, of "dock-to-dock" sales,
which are excluded from net sales due to the Company's policy of recording
only the commission on such transactions as a reduction against cost of goods
sold in the consolidated statements of operations. Dock-to-dock sales
represent large volume sales of pharmaceuticals to major self-warehousing
retail chain pharmacies whereby the Company acts as an intermediary in the
order and subsequent delivery of products to the customers' warehouses.
19
<PAGE> 20
Inventories
Inventories consist of pharmaceutical drugs and related over-the-counter
items, which are stated at the lower of cost or market. Cost is determined
using the first-in, first-out method. See Note 3 for additional information
regarding the change in accounting for determining the cost of inventory.
Property and Equipment
Property and equipment is stated at cost. Depreciation and amortization
are charged to operations primarily using the straight-line method over the
shorter of the estimated useful lives of the various classes of assets, which
vary from 2 to 30 years, or the lease term for leasehold improvements. For
income tax purposes, accelerated depreciation methods are used.
Intangible Assets
Intangible assets are stated at cost less accumulated amortization.
Amortization is determined using the straight-line method over the estimated
useful lives of the related assets.
Long-Lived Assets
If facts and circumstances suggest that a long-lived asset may be impaired,
the carrying value is reviewed. If this review indicates that the carrying
value of the asset will not be recovered, as determined based on projected
undiscounted cash flows related to the asset over its remaining life, the
carrying value of the asset is reduced to its estimated fair value.
Income Taxes
Deferred tax assets and liabilities are recognized for estimated future
tax consequences attributable to differences between the financial statement
carrying amounts of existing assets and liabilities and their respective
basis for income tax purposes. Deferred tax assets and liabilities are
measured and recorded using enacted tax rates in effect for the year in which
those temporary differences are expected to be recovered or settled.
Book Overdrafts
Accounts payable includes book overdrafts (outstanding checks) of $7.6
million and $5.2 million at June 30, 2000 and June 30, 1999, respectively.
Treasury Stock
In May 1999, the board of directors authorized the repurchase of up to
300,000 shares of the Company's outstanding common stock. The shares were
acquired in the open market during the twelve-month period from the date of
authorization. Of the 300,000 shares authorized, 296,400 shares were purchased
during this period.
Earnings per Share
Statement of Financial Accounting Standards No. 128, "Earnings per Share"
(SFAS No. 128) requires a dual presentation of basic and diluted earnings per
share. Basic earnings per share excludes dilution and is computed by dividing
net income by the weighted average number of common shares outstanding for the
period. Diluted earnings per share reflects the potential dilution that would
occur if securities or other contracts to issue common
20
<PAGE> 21
stock were exercised or converted into common stock. All share and per share
amounts have been stated in accordance with the provisions of SFAS No. 128
(see Note 14).
Reclassifications
Certain reclassifications, including the restatement for inventory costing
(see Note 3), have been made to the prior years' financial statements to
conform to the current year presentation.
NOTE 2. ACQUISITIONS:
On June 1, 1999, the Company consummated the acquisition of 100% of the
outstanding stock of Jewett Drug Co. ("Jewett"). Jewett is a pharmaceutical
distribution company based in Aberdeen, South Dakota, that provides
comprehensive pharmaceutical distribution services to customers in the Upper
Midwest and Great Plains region. The aggregate purchase price for this
acquisition of $34.3 million consisted of $21.5 million in cash and $12.8
million (555,556 shares) of the Company's common stock. Funds for the cash
portion of the purchase price were provided by the Company's revolving loan
facility. In connection with the transaction, the Company paid investment
banking fees of $0.8 million to a firm that employs a member of the Company's
Board of Directors.
Also, on June 1, 1999, the Company entered into an amendment to the Amended
and Restated Loan and Security Agreement with Fleet Capital Corporation
pursuant to which the Company's revolving loan facility was increased from $75
million to $95 million and Jewett became a party to, and permitted borrower
under, that facility (See Note 8).
The acquisition was accounted for as a purchase. As such, Jewett results
are included in consolidated operating results from the acquisition date. The
acquisition resulted in goodwill of $30.9 million, which is being amortized
over 25 years.
The following unaudited pro forma information presents a summary of
consolidated results of operations of the Company and Jewett for 1999 and
1998 as if the acquisition had occurred at July 1, 1998, and July 1, 1997,
respectively, with pro forma adjustments to give effect to amortization of
goodwill, interest expense on acquisition debt and certain other adjustments,
together with related income tax effects. The unaudited pro forma
information has been prepared for comparative purposes only and does not
purport to be indicative of the results of operations had these transactions
been completed as of the assumed dates or which may be obtained in the future
(in thousands, except per share amounts).
<TABLE>
<CAPTION>
1999 1998
---- ----
<S> <C> <C>
Net Sales $1,074,047 $807,314
Net Income 7,580 4,332
Diluted earnings per share $1.61 $1.05
</TABLE>
In September 1998, the Company acquired 100% of the stock of Tykon, Inc.,
a wholesale distribution software developer, for cash consideration of $2.0
million. During fiscal 1998, the Company made two acquisitions of
pharmaceutical distribution companies for aggregate consideration of $2.6
million, including cash payments and the issuance of notes payable.
During the year, the Company made certain additional investments in
companies in healthcare-related industries. These investments are accounted
for using the cost mehtod.
NOTE 3. INVENTORIES:
In the fourth quarter of the fiscal year ended June 30, 2000, the Company
changed its method of determining the cost of inventories to the first-in,
first-out (FIFO) method from the last-in, first-out (LIFO) method. The
Company
21
<PAGE> 22
believes FIFO is preferable in that it is more reflective of certain changes to
how its business is currently managed and operated, and therefore, more fairly
reflects the Company's results of operations and financial position.
The effect of the accounting change on previously reported earnings is
shown below:
<TABLE>
<CAPTION>
FOR THE QUARTER ENDED (UNAUDITED)
--------------------------------------------------------------
SEPTEMBER 30, 1999 DECEMBER 31, 1999 MARCH 31, 2000
--------------------------------------------------------------
<S> <C> <C> <C>
Increase in net income (in thousands) $28 $77 $120
Increase in earnings per share
- Basic $0.01 $0.02 $0.03
- Diluted $0.01 $0.02 $0.03
<CAPTION>
FOR THE YEAR ENDED
-----------------------------------------
JUNE 30, 1999 JUNE 30, 1998
-----------------------------------------
<S> <C> <C>
Increase in net income (in thousands) $270 $615
Increase in earnings per share
- Basic $0.07 $0.19
- Diluted $0.06 $0.17
</TABLE>
NOTE 4. PROPERTY AND EQUIPMENT:
Property and equipment consisted of the following (in thousands):
<TABLE>
<CAPTION>
JUNE 30, 2000 JUNE 30, 1999
------------- -------------
<S> <C> <C>
Land $ 383 $ 383
Building and improvements 3,870 3,758
Fixtures and equipment 9,137 7,139
Leasehold improvements 1,981 828
Vehicles 674 737
----------------------------------
16,045 12,845
Less-Accumulated depreciation and
amortization (7,861) (6,640)
----------------------------------
$ 8,184 $ 6,205
==================================
</TABLE>
The Company leases certain properties under capital leases. Capital lease
asset balances consist of buildings of $0.9 million as of June 30, 2000.
NOTE 5. INVESTMENT IN PBI:
In November 1995, the Company purchased approximately 50% of the capital
stock of Pharmaceutical Buyers, Inc. ("PBI"), a Colorado-based group purchasing
organization. Pursuant to the transaction, the Company acquired approximately
50% of the voting and non-voting common stock of PBI for $3.75 million in cash.
The Company's investment in PBI is accounted for under the equity method.
The Company's equity in the net income of PBI totaled $634,000, $332,000,
and $389,000, respectively, for 2000, 1999, and 1998, which is net of
amortization of goodwill associated with its investment in PBI of $276,000 for
each of these years. The PBI goodwill is being amortized using the
straight-line method over a period of 25 years. During 2000, 1999, and 1998,
the Company received cash dividends of $350,000 in each year from PBI, which
were recorded as a reduction in the carrying amount of the investment.
22
<PAGE> 23
Summarized balance sheet information for PBI for its fiscal year ended
December 31, 1999 and unaudited information for the periods ended June 30, 2000
and 1999 included (in millions):
<TABLE>
<CAPTION>
(UNAUDITED)
-------------------------------------
DECEMBER 31, 1999 JUNE 30, 2000 JUNE 30, 1999
----------------- ------------- -------------
<S> <C> <C> <C>
Current assets $ 2.7 $ 2.7 $ 3.0
Non-current assets 0.6 0.6 0.5
Current liabilities 1.7 1.5 1.9
Non-current liabilities 4.3 4.3 5.1
</TABLE>
Summarized income statement information for PBI for its fiscal year ended
December 31, 1999 and unaudited information for the six months ended June 30,
2000, 1999 and 1998 included (in millions):
<TABLE>
<CAPTION>
SIX MONTHS ENDED (UNAUDITED)
12 MONTHS ENDED -------------------------------------------------
DECEMBER 31, 1999 JUNE 30, 2000 JUNE 30, 1999 JUNE 30, 1998
----------------- ------------- ------------- -------------
<S> <C> <C> <C> <C>
Net revenue $ 5.8 $ 2.9 $ 2.7 $ 2.8
Net income 1.5 0.8 0.6 0.6
</TABLE>
Certain other shareholders of PBI have the option to exchange their
combined 20% ownership interests in PBI for shares of the Company's common
stock under the terms of the original purchase agreement. Those options have
been determined to be dilutive in 2000 and 1999 and are included in the
reconciliation of the basic and the diluted earnings per share computation
(See Note 14).
NOTE 6. OTHER ASSETS:
Other assets include deferred debt issuance costs of $1.2 million and $.9
million, respectively, at June 30, 2000 and June 30, 1999 that are being
amortized over the periods the related debt is outstanding. Accumulated
amortization amounted to $0.7 million and $0.4 million at June 30, 2000 and
June 30, 1999, respectively. Amortization of deferred debt issuance costs
totaled $375,000 in 2000, $188,000 in 1999, and $59,000 in 1998, and is
included in interest expense in the consolidated statements of operations.
NOTE 7. INTANGIBLE ASSETS:
Intangible assets consisted of the following (in thousands):
<TABLE>
<CAPTION>
JUNE 30, 2000 JUNE 30, 1999
------------- -------------
<S> <C> <C>
Excess of purchase price over fair value of net assets acquired $50,461 $49,927
Less-Accumulated amortization (7,945) (6,118)
------------------------------------
$42,516 $43,809
====================================
</TABLE>
The excess of purchase price over the fair value of net assets acquired is
being amortized using the straight-line method over periods of 10 to 40 years.
Amortization of intangible assets totaled $1.8 million in 2000, $0.6 million in
1999, and $0.4 million in 1998.
23
<PAGE> 24
NOTE 8. LONG-TERM DEBT:
Long-term debt consists of the following (in thousands):
<TABLE>
<CAPTION>
JUNE 30, 2000 JUNE 30, 1999
------------- -------------
<S> <C> <C>
Revolving line of credit with banks $97,990 $39,453
Other, including capital lease obligations 1,962 1,399
------------------------------------
99,952 $40,852
Less--Current maturities (305) (403)
------------------------------------
$99,647 $40,449
====================================
</TABLE>
As of June 30, 2000, the revolving line of credit had a maximum borrowing
capacity of $120 million, expiring in August 2001. Prior to December 1999,
the revolving line of credit had maximum borrowing capacity of $95.0 million.
Under the loan agreement, the total amount of loans and letters of credit
outstanding at any time may not exceed the lesser of an amount based on
percentages of eligible inventories (the borrowing base formula), or the
maximum borrowing capacity. In December 1999, an additional seasonal line of
credit was added to this facility increasing the maximum borrowing capacity
to $120 million during a seasonal period. Such seasonal period starts on or
after October 1 but not later than December 1 of each year and continues
until six months after the commencement of such seasonal period, which was
extended through September 30, 2000 for the current fiscal year. Generally,
advances bear interest at the London Interbank Offered Rate (LIBOR) (6.68% at
June 30, 2000) plus 1.75% or at the prime rate (8.43% at June 30, 2000) plus
.25% per annum payable monthly. On May 4, 2000, the Company fixed $20
million of its revolving line of credit at a nominal rate of 7.30%. The
Company was required to pay annual facility fees of $398,250 and $201,000,
respectively, in 2000 and 1999. At June 30, 2000 and June 30, 1999, the
borrowing base formula amounted to $135.0 million and $106.8 million,
respectively. At June 30, 2000 and June 30, 1999, the unused portion of the
line of credit amounted to $22.0 million and $55.5 million, respectively.
The agreement expires August 7, 2001, and, therefore, the related debt has
been classified as long-term. The revolving line of credit is secured by
eligible inventories.
In the first quarter of fiscal 1999, the Company entered into a $45 million
accounts receivable purchase facility under an asset securitization structure
(the "Securitization") with its primary lender. In the second quarter of fiscal
1999, the Securitization was increased to $60 million and to $75 million in the
fourth fiscal quarter of 2000. The Securitization has an initial term of three
years, with annual renewal options, and bears interest at the LIBOR rate plus
program and liquidity fees of 0.71% paid monthly. The Company was required to
pay an original structuring fee of $225,000 plus an additional $75,000 for the
increase in the facility, both of which are being amortized over the remaining
term of the arrangement. Under the Securitization, accounts receivable are
sold on a non-recourse basis to a bankruptcy-remote subsidiary of the Company
as security for commercial paper issued by an affiliate of the lender. Based
upon the structure of the arrangement, the subsidiary's assets and liabilities,
consisting of accounts receivable and long-term debt, are not consolidated with
those of the Company. Accordingly, the company's trade accounts receivable at
June 30, 2000 and 1999 are net of $75.0 million and $35.0 million,
respectively, which represent accounts receivable that were sold under the
Securitization.
The Company also has an interest rate collar agreement, whereby the LIBOR
on $10 million of the outstanding revolving line of credit balance shall not
exceed 6.75%. If the LIBOR is less than 5.25%, then the LIBOR rate on $7.5
million of the outstanding revolving line of credit balance shall not be less
than 5.25%. The Company has an additional interest rate collar agreement on
$40 million of the outstanding revolving line of credit, whereby the LIBOR
shall not exceed 6.85% nor be less than 4.93%. At June 30, 2000, the
approximate value of these instruments was $115,000. Both of these agreements
expire in August 2001.
24
<PAGE> 25
The Company is required under the terms of its debt agreements to comply
with certain financial covenants, including those related to the maintenance of
current ratio, tangible net worth and debt service and interest coverage
ratios. The Company also is limited in its ability to make loans and
investments, enter into leases, make capital expenditures or incur additional
debt, among other things, without the consent of its lenders.
In June 2000, the Company entered into a $965,000 equipment financing
arrangement with a 5-year term ending July 2005. The arrangement provides
for monthly payments bearing interest at LIBOR plus 1.95%. This arrangement
is secured by the equipment purchased with the proceeds.
At June 30, 2000, maturities of long-term debt, including capital lease
obligations, were as follows (in thousands):
<TABLE>
<CAPTION>
FISCAL YEAR ENDING JUNE 30,
---------------------------
<S> <C>
2001 $ 305
2002 98,311
2003 340
2004 369
2005 401
Thereafter 226
---------
$99,952
=========
</TABLE>
At June 30, 2000 and June 30, 1999, the fair value of long-term debt
approximated its current carrying value.
NOTE 9. COMMITMENTS AND CONTINGENCIES:
The Company leases office and warehouse space and other equipment through
noncancelable operating leases. Rental expense under operating leases was
$1.9 million, $0.9 million, and $0.9 million in 2000, 1999, and 1998,
respectively. Minimum rental payments under these leases with initial or
remaining terms of one year or more at June 30, 2000, are $8.7 million and
payments during the succeeding five years are: 2001, $2.1 million; 2002, $2.0
million; 2003, $1.9 million; 2004, $1.3 million; 2005, $1.0 million; and
thereafter $0.4 million.
There are various pending claims and lawsuits arising out of the normal
course of the Company's business. In the opinion of management, the ultimate
outcome of these claims and lawsuits will not have a material adverse effect on
the financial position or results of operations of the Company.
NOTE 10. STOCK OPTIONS:
In 1992, the Company adopted a Long-Term Incentive Plan that authorized the
Compensation Committee of the Board of Directors (the Committee) to grant key
employees and officers of the Company incentive or non-qualified stock options,
stock appreciation rights, performance shares, restricted shares and
performance units. Options to purchase up to 200,000 shares of common stock
were authorized under the Long-Term Incentive Plan. The Committee determines
the price (generally no less than fair market value on the date of grant) and
terms at which awards may be granted, along with the duration of the
restriction periods and performance targets. In 1999, the Company's
shareholders approved an Amended and Restated Long-Term Incentive Plan
(Long-Term Incentive Plan) that increased the number of shares available for
grant to 850,000 shares. Stock options granted under the Long-Term Incentive
Plan are not exercisable earlier than six months from the date of grant
(except in the case of death or disability of the employee holding the same),
nor later than ten years from the date of grant.
In February 1993, the Board of Directors of the Company adopted the D&K
Wholesale Drug, Inc. 1993 Stock Option Plan (the 1993 Plan) to grant key
employees of the Company non-qualified stock options to purchase up to
350,000 shares of the Company's common stock. The 1993 Plan is administered
by the Company's Board of
25
<PAGE> 26
Directors, which determines the price and terms at which awards may be
granted. Stock options granted under the 1993 Plan are immediately
exercisable from the date of grant and expire not later than ten years from
the date of grant. The exercise price of all options granted pursuant to the
1993 Plan was equal to the fair market value of stock on the respective dates
of grant.
Changes in options outstanding under the Company's Long-Term Incentive Plan
and the 1993 Plan are as follows:
<TABLE>
<CAPTION> Weighted Average
Number of Shares Exercise Price
---------------- ----------------
<S> <C> <C>
OUTSTANDING AT JUNE 30, 1997 295,199 $ 4.36
Granted 1998 175,999 11.30
Exercised 1998 (29,200) 4.26
------------------------------------------
OUTSTANDING AT JUNE 30, 1998 441,998 7.13
Granted 1999 169,200 19.64
Exercised 1999 (112,000) 7.33
Canceled 1999 (3,000) 11.25
------------------------------------------
OUTSTANDING AT JUNE 30, 1999 496,198 11.32
Granted 2000 165,000 20.23
Exercised 2000 (80,200) 4.72
Canceled 2000 (321,800) 20.40
------------------------------------------
OUTSTANDING AT JUNE 30, 2000 259,198 $ 7.77
</TABLE>
Stock options exercisable at June 30, 2000, June 30, 1999, and June 30,
1998 were 249,198, 451,198, and 409,998, respectively, with a weighted average
exercise price of $7.42, $10.12, and $6.43, respectively. At June 30, 2000,
the exercisable options had exercise prices ranging from $3.38 to $24.38. The
weighted average remaining contractual terms for all outstanding options was
5.44 years at June 30, 2000.
In accordance with the provisions of Statement of Financial Accounting
Standards No. 123, "Accounting for Stock-Based Compensation" (SFAS 123), the
Company has elected to account for its stock-based compensation plans under
Accounting Principles Board Opinion No. 25, "Accounting for Stock Issued to
Employees." Accordingly, no compensation expense has been recognized in the
consolidated financial statements for the stock option plans. If the Company
had elected to recognize compensation expense based upon the fair value of
the options granted at the grant date as prescribed by SFAS 123, pro forma
net income and earnings per share would have been as follows (in thousands,
except per share data):
<TABLE>
<CAPTION>
2000 1999 1998
---- ---- ----
<S> <C> <C> <C>
Net income - as reported $8,199 $6,625 $3,942
Net income - pro forma $7,027 $5,046 $3,007
Earnings per share:
Basic - as reported $1.93 $1.72 $1.18
Basic - pro forma $1.66 $1.31 $0.90
Diluted - as reported $1.84 $1.58 $1.07
Diluted - pro forma $1.58 $1.20 $0.82
</TABLE>
The fair value of each option grant was estimated on the date of the
grant using the Black-Scholes option-pricing model using the following
weighted-average assumptions:
<TABLE>
<CAPTION>
2000 1999 1998
---- ---- ----
<S> <C> <C> <C>
Risk free interest rates 6.30% 4.89% 5.50%
Expected life of options 5.0 years 5.0 years 5.0 years
Volatility of stock price 130% 116% 138%
Expected dividend yield 0% 0% 0%
Fair value of options granted $18.61 $16.25 $10.13
</TABLE>
26
<PAGE> 27
NOTE 11. WARRANTS:
In June 1994, the Company entered into a letter agreement with an
independent research firm to produce reports with respect to the Company's
publicly traded equity securities. In 1998, the research firm exercised the
warrants, resulting in the issuance of 70,000 shares of common stock of the
Company, recorded as additional equity of $288,750.
NOTE 12. INCOME TAXES:
The components of the income tax provision were as follows (in thousands):
<TABLE>
<CAPTION>
2000 1999 1998
---- ---- ----
<S> <C> <C> <C>
Current tax provision $4,893 $3,354 $ 933
Deferred tax provision 307 658 1,618
-----------------------------------------------
Income tax provision $5,200 $4,012 $2,551
===============================================
</TABLE>
The actual income tax provision differs from the expected income tax
provision, computed by applying the U.S. statutory Federal tax rates of 34.1%,
34%, and 34% in 2000, 1999 and 1998, respectively, to income before income tax
provision, as follows (in thousands):
<TABLE>
<CAPTION>
2000 1999 1998
---- ---- ----
<S> <C> <C> <C>
Current expected income tax provision $4,570 $3,617 $2,208
Amortization of intangible assets not
deductible for income tax purposes 203 202 222
Equity in net income of PBI not taxable
for income tax purposes (248) (166) (181)
State income taxes, net of Federal benefit 569 439 293
Other, net 106 (80) 9
------------------------------------------------
$5,200 $4,012 $2,551
================================================
</TABLE>
At June 30, 2000 and June 30, 1999, the tax effects of temporary
differences that give rise to significant portions of the Company's deferred
tax assets and liabilities are as follows (in thousands):
<TABLE>
<CAPTION>
2000 1999
---- ----
<S> <C> <C>
Deferred tax assets:
Allowance for doubtful accounts $ 564 $ 457
Accrued liabilities 771 577
Capital lease obligations 112 104
Inventories 1,001 948
Net operating loss carryforwards 102 2,275
Alternative minimum tax and contribution carryforwards -- 32
Other 171 136
------------------------------
Total deferred tax assets $ 2,721 $ 4,529
------------------------------
Deferred tax liabilities:
Property and equipment ($ 467) ($ 454)
Inventories (5,657) (7,479)
Intangibles (407) (407)
Accounts receivable (154) (233)
Other (464) (114)
------------------------------
Total deferred tax liabilities ($ 7,149) ($8,687)
------------------------------
Net deferred tax liabilities ($ 4,428) ($4,158)
==============================
</TABLE>
27
<PAGE> 28
In connection with the change in accounting for inventory from the LIFO
method to the FIFO method (See Note 3), net deferred tax liabilities of $5.7
million represent the tax impact of this change. The use of pre-acquisition
operating losses is subject to limitations imposed by the Internal Revenue Code
and if not utilized by the Company, the net operating loss carryforwards will
expire beginning in 2007.
NOTE 13. EMPLOYEE BENEFIT PLANS
The Company has a defined contribution 401(k) plan covering substantially
all of its employees. Plan participants may contribute up to 20% of their
annual compensation, subject to certain limitations. The Company contribution
is discretionary and was equivalent to 25% of employees' contributions up to a
maximum contribution based on 6% of eligible compensation through December
31, 1999. On January 1, 2000 the discretionary match was raised to 50% of
employees' contributions up to a maximum contribution based on 6% of eligible
compensation. Expenses related to the plan were $176,000 in 2000, $66,000 in
1999, and $45,000 in 1998. Jewett has a defined contribution 401(k)/profit
sharing plan covering substantially all of its employees. Jewett made a
discretionary contribution of $100,000 to this plan in 2000. Jewett also
participates in the Central States Pension, a multiemployer pension plan, on
behalf of its union employees in accordance with the union agreement. The
expenses relating to this plan during 2000 were approximately $17,000.
The Company also has an executive retirement benefit plan, implemented in
1998, that provides supplemental pre-retirement life insurance plus
supplemental retirement income to key executives. The life insurance benefit is
calculated at 3 times the participant's annual salary. The retirement income
benefit is provided through discretionary contributions to each participant's
account, which vest 20% annually and are fully vested upon attaining age 65.
Upon retirement, the accumulated account balance is paid to the participant
over 15 years in quarterly benefit payments. The Company's expense related to
the plan was $213,000 in 2000, $245,000 in 1999, and $176,000 in 1998.
28
<PAGE> 29
NOTE 14. EARNINGS PER SHARE:
The Company adopted SFAS 128 in 1998. All earnings and share amounts
have been restated in accordance with SFAS 128.
The reconciliation of the numerator and denominator of the basic and
diluted earnings per common share computations are as follows (in thousands,
except for shares and per share amounts):
<TABLE>
<CAPTION>
2000
--------------------------------------------------
INCOME SHARES PER-SHARE
(NUMERATOR) (DENOMINATOR) AMOUNT
----------- ------------- ------
<S> <C> <C> <C>
BASIC EARNINGS PER SHARE:
Net income available to common shareholders $8,199 4,240,951 $1.93
---------------------------------
EFFECT OF DILUTED SECURITIES:
Options and warrants 108,925
Convertible PBI stock 152 200,000
---------------------------------
DILUTED EARNINGS PER SHARE:
Net income available to common shareholders
plus assumed conversions $8,351 4,549,876 $1.84
---------------------------------
<CAPTION>
1999
--------------------------------------------------
INCOME SHARES PER-SHARE
(NUMERATOR) (DENOMINATOR) AMOUNT
----------- ------------- ------
<S> <C> <C> <C>
BASIC EARNINGS PER SHARE:
Net income available to common shareholders $6,625 3,846,837 $1.72
EFFECT OF DILUTED SECURITIES:
Options and warrants 173,039
Convertible PBI stock 41 200,000
---------------------------------
DILUTED EARNINGS PER SHARE:
Net income available to common shareholders
plus assumed conversions $6,666 4,219,876 $1.58
---------------------------------
<CAPTION>
1998
--------------------------------------------------
INCOME SHARES PER-SHARE
(NUMERATOR) (DENOMINATOR) AMOUNT
----------- ------------- ------
<S> <C> <C> <C>
BASIC EARNINGS PER SHARE:
Net income available to common shareholders $3,942 3,345,261 $1.18
EFFECT OF DILUTED SECURITIES:
Options and warrants 138,940
Convertible subordinated notes 70 282,151
---------------------------------
DILUTED EARNINGS PER SHARE:
Net income available to common shareholders
plus assumed conversions $4,012 3,766,352 $1.07
---------------------------------
</TABLE>
NOTE 15. EFFECT OF NEW ACCOUNTING STANDARDS:
In June, 1998, the Financial Accounting Standards Board issued SFAS No.
133, "Accounting for Derivative Instruments and Hedging Activities," which is
required to be adopted in years beginning after June 15, 2000. Accordingly,
the Company adopted the provisions of this statement on July 1, 2000,
resulting in an increase in stockholders' equity of approximately $69,000.
NOTE 16. BUSINESS SEGMENTS:
During the fourth quarter of fiscal 1999, the Company adopted SFAS No.
131. This statement establishes standards for the way public companies
report information about operating segments that is consistent with that made
available to management of the Company in allocating resources and assessing
performance.
29
<PAGE> 30
After application of the aggregation criteria, the Company has three
identifiable business segments, only one of which, Wholesale drug
distribution, meets the quantitative thresholds for separate disclosure
prescribed in SFAS No. 131. This segment is described in Note 1. The
Company's equity investment in PBI (see Note 5) is a second segment. Two
wholly owned software subsidiaries; Viking Computer Services, Inc. and Tykon,
Inc. constitute the third segment. Viking markets a pharmacy management
software system and Tykon developed and markets a proprietary PC-based order
entry/order confirmation system to the drug distribution industry. These two
segments are combined as Other in the table that follows.
Though the Wholesale drug distribution segment operates from several
different facilities, the nature of its products and services, the types of
customers and the methods used to distribute its products are similar and
thus they have been aggregated for presentation purposes. The Company
operates principally in the United States. Intersegment sales have been
recorded at amounts approximating market. Interest and corporate expenses
are allocated to wholly owned subsidiaries only. Assets have been identified
with the segment to which they relate.
<TABLE>
<CAPTION>
(in thousands) For the Years Ended
----------------------------------------------------
JUNE 30, 2000 JUNE 30, 1999 JUNE 30, 1998
------------- ------------- -------------
<S> <C> <C> <C>
Sales to unaffiliated customers --
Wholesale drug distribution $1,455,421 $813,287 $611,498
Other 2,626 2,032 929
-----------------------------------------------------
Total $1,458,047 $815,319 $612,427
Intersegment sales --
Wholesale drug distribution $ -- $ -- $ --
Other 329 75 --
Intersegment eliminations (329) (75) --
-----------------------------------------------------
Total $ -- $ -- $ --
Net sales --
Wholesale drug distribution $1,455,421 $813,287 $611,498
Other 2,955 2,107 929
Intersegment eliminations (329) (75) --
-----------------------------------------------------
Total $1,458,047 $815,319 $612,427
Gross profit --
Wholesale drug distribution $ 53,923 $ 39,549 $ 29,882
Other 2,499 1,987 772
-----------------------------------------------------
Total $ 56,422 $ 41,536 $ 30,654
Depreciation and amortization --
Wholesale drug distribution $ 3,160 $ 1,457 $ 1,429
Other 234 466 315
Less: PBI amortization <F1> (276) (276) (276)
-----------------------------------------------------
Total $ 3,118 $ 1,647 $ 1,468
Interest expense -
Wholesale drug distribution $ 10,517 $ 5,260 $ 4,075
Other 126 6 5
-----------------------------------------------------
Total $ 10,643 $ 5,266 $ 4,080
Earnings before income tax provision -
Wholesale drug distribution $ 12,692 $ 10,073 $ 6,792
Other 707 564 (299)
-----------------------------------------------------
Total $ 13,399 $ 10,637 $ 6,493
Purchases of property and equipment -
Wholesale drug distribution $ 1,913 $ 292 $ 337
Other 111 10 9
Other unallocated Corporate amounts <F2> 1,246 577 517
-----------------------------------------------------
Total $ 3,270 $ 879 $ 863
Identifiable assets -
Wholesale drug distribution $ 422,508 $239,639 $172,090
Other 10,141 6,740 4,232
Other unallocated Corporate amounts <F2> 3,391 3,737 4,887
Elimination of receivables from Corporate (141,621) (13,126) (2,838)
-----------------------------------------------------
Total $ 294,419 $236,990 $178,371
<FN>
<F1> Amortization of PBI goodwill is netted against Equity in net income of PBI
in the accompanying Consolidated Statements of Operations.
<F2> Amounts represent assets at Corporate Headquarters consisting primarily of
deferred tax assets, property and equipment and deferred debt costs.
</TABLE>
30
<PAGE> 31
NOTE 17. QUARTERLY RESULTS (UNAUDITED)
Quarterly results are determined in accordance with annual accounting
policies. They include certain items based upon estimates for the entire
year. Summarized quarterly results, restated for the change in accounting
for inventory valuation (see Note 3), for the last two years were as follows:
<TABLE>
<CAPTION>
(in thousands, except per share data) 2000 QUARTER 2000
------------------------------------------------------ ----------
FIRST SECOND THIRD FOURTH YEAR
<S> <C> <C> <C> <C> <C>
Net Sales $323,565 $336,898 $427,236 $370,348 $1,458,047
Gross profit 11,865 13,126 15,459 15,972 56,422
Income before income tax provision 2,621 2,875 4,225 3,678 13,399
Net income 1,612 1,768 2,598 2,221 8,199
Basic earnings per share $0.37 $0.42 $0.63 $0.53 $1.93
Diluted earnings per share 0.35 0.39 0.59 0.51 1.84
<CAPTION>
(in thousands, except per share data) 1999 QUARTER 1999
------------------------------------------------------ ----------
FIRST SECOND THIRD FOURTH YEAR
<S> <C> <C> <C> <C> <C>
Net Sales $179,374 $198,345 $213,984 $223,616 $815,319
Gross profit 8,581 10,051 13,135 9,769 41,536
Income before income tax provision 2,059 2,478 4,330 1,770 10,637
Net income 1,238 1,533 2,650 1,204 6,625
Basic earnings per share $0.33 $0.40 $0.69 $0.30 $1.72
Diluted earnings per share 0.31 0.37 0.63 0.27 1.58
</TABLE>
31
<PAGE> 32
Item 9. Changes in and Disagreements with Accountants on Accounting
------ -----------------------------------------------------------
and Financial Disclosure
------------------------
None.
PART III
Item 10. Directors and Executive Officers of the Registrant
------- --------------------------------------------------
The information set forth under the captions "Election of Directors" in
the registrant's Proxy Statement for its 2000 Annual Meeting of Stockholders
(the "2000 Proxy Statement") is incorporated herein by this reference. The
Company will file the 2000 Proxy Statement with the Commission pursuant to
Regulation 14A within 120 days after the close of the fiscal year.
Information regarding executive officers is set forth in Part I of this
report.
Item 11. Executive Compensation
------- ----------------------
The information set forth under the captions "Directors' Fees" and
"Compensation of Executive Officers" in the registrant's 2000 Proxy Statement
is incorporated herein by this reference.
Item 12. Security Ownership of Certain Beneficial Owners and Management
------- --------------------------------------------------------------
The information set forth under the captions "Voting Securities and
Principal Holders Thereof" and "Security Ownership By Management" in the
registrant's 2000 Proxy Statement is incorporated herein by this reference.
Item 13. Certain Relationships and Related Transactions
------- ----------------------------------------------
The information set forth under the caption "Certain Transactions" in the
registrant's 2000 Proxy Statement is incorporated herein by this reference.
Item 14. Exhibits, Financial Statements, Schedules and Reports on Form 8-K
------- -----------------------------------------------------------------
(a)(1) Financial statements: See Item 8 above.
(2) The following financial statement schedule and auditors'
report thereon are included in Part IV of this report:
Page
----
Schedule II - Valuation and Qualifying Accounts 34
Schedules other than those listed above have been omitted because they
are either not required or not applicable, or because the information is
presented in the consolidated financial statements or the notes
thereto.
(3) Exhibits.
See Exhibit Index.
(b) Reports on Form 8-K
None.
(c) See Item 14(a)(3) above.
(d) See Item 14(a)(2) above.
32
<PAGE> 33
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.
D & K HEALTHCARE RESOURCES, INC.
(Registrant)
By /s/ J. Hord Armstrong, III
----------------------------------------------
J. Hord Armstrong, III, Chairman of the Board,
Chief Executive Officer and Treasurer
Date: September 21, 2000
Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.
<TABLE>
<CAPTION>
Signature Title Date
--------- ----- ----
<S> <C> <C>
/s/ J. Hord Armstrong, III Chairman, Chief Executive Officer, September 21, 2000
----------------------------- Treasurer and Director
J. Hord Armstrong, III
/s/ Martin D. Wilson President, Chief Operating Officer September 21, 2000
----------------------------- and Director
Martin D. Wilson
/s/ Thomas S. Hilton Senior Vice President, Chief Financial September 21, 2000
----------------------------- Officer (Principal financial and accounting officer)
Thomas S. Hilton
/s/ Richard F. Ford Director September 21, 2000
-----------------------------
Richard F. Ford
/s/ Bryan H. Lawrence Director September 21, 2000
-----------------------------
Bryan H. Lawrence
/s/ Robert E. Korenblat Director September 21, 2000
-----------------------------
Robert E. Korenblat
/s/ Thomas F. Patton Director September 21, 2000
-----------------------------
Thomas F. Patton
/s/ James M. Usdan Director September 21, 2000
-----------------------------
James M. Usdan
/s/ Louis B. Susman Director September 21, 2000
-----------------------------
Louis B. Susman
/s/ Harvey C. Jewett, IV Director September 21, 2000
-----------------------------
Harvey C. Jewett, IV
</TABLE>
33
<PAGE> 34
<TABLE>
D & K HEALTHCARE RESOURCES, INC. AND SUBSIDIARIES
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS FOR
FISCAL 1998, FISCAL 1999, AND FISCAL 2000
<CAPTION>
Additions
--------------------------
Balance at Charged to Balance at
Beginning Costs and End of
of Period Expenses Acquisitions Deductions Period
--------- -------- ------------ ---------- ------
<S> <C> <C> <C> <C> <C>
Valuation Allowances for
Doubtful Receivables:
Fiscal Year 1998 $ 697,000 $ 15,000 $28,000 $(40,000) $ 700,000
========== ======== ======= ========= ==========
Fiscal Year 1999 $ 700,000 $365,000 $82,000 $ (5,000) $1,142,000
========== ======== ======= ========= ==========
Fiscal Year 2000 $1,142,000 $269,000 $ 0 $ (0) $1,411,000
========== ======== ======= ========= ==========
</TABLE>
34
<PAGE> 35
<TABLE>
EXHIBIT INDEX
-------------
Exhibit No. Description
----------- -----------
<C> <S>
2.1<F*> Stock Purchase and Redemption Agreement, dated as of November 30,
1995, by and among Pharmaceutical Buyers, Inc., J. David McCay,
The J. David McCay Living Trust, Robert E. Korenblat and the
registrant filed as an exhibit to the registrant's Annual Report
on Form 10-K for the year ended March 28, 1997.
2.2<F*> Stock Purchase Agreement dated June 1, 1999 by and between the
registrant and Harvey C. Jewett, IV, filed as an exhibit to Form
8-K dated June 14, 1999.
3.1<F*> Restated Certificate of Incorporation, filed as an exhibit to
registrant's Registration Statement on Form S-1 (Reg. No.
33-48730).
3.2<F*> Certificate of Amendment to the Restated Certificate of
Incorporation of D&K Wholesale Drug, Inc filed as an exhibit to
the registrant's Annual Report on Form 10-K for the year ended
June 30, 1998.
3.3<F*> By-laws of the registrant, as currently in effect, filed as an
exhibit to registrant's Registration Statement on Form S-1 (Reg.
No. 33-48730).
4.1<F*> Form of certificate for Common Stock, filed as an exhibit to
registrant's Registration Statement on Form S-1 (Reg. No.
33-48730).
4.2<F*> Form of Rights Agreement dated as of November 12, 1998 between
registrant and Harris Trust and Savings Bank as Rights Agent,
which includes as Exhibit B the form of Right Certificate, filed
as an exhibit to Form 8-K dated November 17, 1998.
10.1<F*> D & K Healthcare Resources, Inc., Amended and Restated 1992 Long
Term Incentive Plan, filed as Annex A to the registrant's 1999
Proxy Statement.
10.2<F*> D & K Wholesale Drug, Inc. 401(k) Profit Sharing Plan and Trust,
dated January 1, 1995, filed as an exhibit to the registrant's
Annual Report on Form 10-K for the year ended March 29, 1996.
10.2a<F**> Amendment Number 1 to D & K Wholesale Drug, Inc. 401(k) Profit
Sharing Plan and Trust, dated December 20, 1996.
10.2b<F**> Amendment Number 2 to D & K Wholesale Drug, Inc. 401(k) Profit
Sharing Plan and Trust, dated September 17, 1997
10.2c<F**> Resolution to D & K Wholesale Drug, Inc. 401(k) Profit Sharing
Plan and Trust, dated March 27, 2000.
10.3<F*> Amended and Restated Lease Agreement, dated as of January 16,
1996, by and between Morhaert Development, L.L.C. and the
registrant, filed as an exhibit to the registrant's Annual Report
on Form 10-K for the year ended March 29, 1996.
35
<PAGE> 36
EXHIBIT INDEX
-------------
<CAPTION>
Exhibit No. Description
----------- -----------
<C> <S>
10.4<F*> Purchase and Sale Agreement dated as of August 7, 1998 between
registrant, certain of its subsidiaries and D&K Receivables
Corporation, filed as an exhibit to the registrant's Annual Report
on Form 10-K for the year ended June 30, 1998.
10.5<F*> Fourth Amended and Restated Loan and Security Agreement dated as
of August 7, 1998 among registrant, Jaron Inc., and Fleet Capital
Corporation, filed as an exhibit to the registrant's Annual Report
on Form 10-K for the year ended June 30, 1998.
10.5a<F*> First Amendment to Fourth Amended and Restated Loan and Security
Agreement, dated as of November 25, 1998, by and among Fleet
Capital Corporation, the registrant and Jaron, Inc. filed as an
exhibit to the registrant's Annual Report on Form 10-K for the
year ended June 30, 1999.
10.5b<F*> Second Amendment to Fourth Amended and Restated Loan and Security
Agreement, dated as of June 1, 1999, by and among Fleet Capital
Corporation, the registrant, Jaron, Inc., and Jewett Drug Co.
filed as an exhibit on Form 8-K dated June 14, 1999.
10.5c<F*> Third Amendment to Fourth Amended and Restated Loan and Security
Agreement, dated as of June 30, 1999, by and among Fleet Capital
Corporation, the registrant, Jaron, Inc., and Jewett
Drug Co, filed as an exhibit to the registrant's Annual Report on
Form 10-K for the year ended June 30, 1999.
10.5d<F*> Fourth Amendment to the Fourth Amended and Restated Loan and
Security Agreement, dated December 17, 1999 between registrant and
Fleet Capital Corporation, filed as an exhibit to the registrant's
Quarterly Report on Form 10-Q for the quarter ended December 31,
1999.
10.5e<F*> Fifth Amendment to the Fourth Amended and Restated Loan and
Security Agreement, dated February 29, 2000 between registrant and
Fleet Capital Corporation, filed as an exhibit to the registrant's
Quarterly Report on Form 10-Q for the quarter ended March 31,
2000.
10.5f<F**> Seventh Amendment to the Fourth Amended and Restated Loan and
Security Agreement, dated May 31, 2000 between registrant and
Fleet Capital Corporation.
10.5g<F**> Eighth Amendment to the Fourth Amended and Restated Loan and
Security Agreement, dated June 30, 2000 between registrant and
Fleet Capital Corporation.
10.5h<F**> Ninth Amendment to the Fourth Amended and Restated Loan and
Security Agreement, dated August 31, 2000 between registrant and
Fleet Capital Corporation.
10.6<F*> Receivables Purchase Agreement dated as of August 7, 1998 among
D&K Receivables Corporation, registrant, Blue Keel Funding, LLC
and Fleet National Bank, filed as an exhibit to the registrant's
Annual Report on Form 10-K for the year ended June 30, 1998.
10.6a<F**> First Amendment to Receivable Purchase Agreement, dated December
17, 1998 between registrant, Blue Keel Funding, LLC and Fleet
National Bank.
36
<PAGE> 37
EXHIBIT INDEX
-------------
<CAPTION>
Exhibit No. Description
----------- -----------
<C> <S>
10.6b<F**> Second Amendment to Receivable Purchase Agreement, dated June 1,
1999 between registrant, Blue Keel Funding, LLC and Fleet National
Bank.
10.6c<F*> Third Amendment to Receivable Purchase Agreement, dated March 31,
2000 between registrant, Blue Keel Funding, LLC and Fleet National
Bank, filed as an exhibit to the registrant's Quarterly Report on
Form 10-Q for the quarter ended March 31, 2000.
10.7<F***> Prime Vendor Agreement dated as of August 25, 1999, between
Tennessee Pharmacy Purchasing Alliance and the registrant, filed
as an exhibit to the registrant's Annual Report on Form 10-K for
the year ended June 30, 1999.
10.8<F*> Lease Agreement, dated as of May 18, 1999, by and between BSRT
Lexington Trust and the registrant, filed as an exhibit to the
registrant's Annual Report on Form 10-K for the year ended June
30, 1999.
10.9<F*> Lease Agreement, dated as of January 1, 1997, by and between
Jewett Family Investments, LLC and Jewett Drug Co, filed as an
exhibit to the registrant's Annual Report on Form 10-K for the
year ended June 30, 1999.
10.10<F*> First Amendment to Lease, dated as of June 1, 1999, by and between
Jewett Family Investments, LLC and Jewett Drug Co, filed as an
exhibit to the registrant's Annual Report on Form 10-K for the
year ended June 30, 1999.
10.11<F*> Lease Agreement dated as of July 1, 1997 by and between Jewett
Family Investments, LLC and the registrant, filed as an exhibit to
the registrant's Annual Report on Form 10-K for the year ended
June 30, 1999.
10.12<F*> First Amendment to Lease, dated as of June 1, 1999, by and between
Jewett Family Investments, LLC and Jewett Drug Co, filed as an
exhibit to the registrant's Annual Report on Form 10-K for the
year ended June 30, 1999.
10.13<F**> Employment agreement for J. Hord Armstrong, III dated September
15, 2000.
10.14<F**> Employment agreement for Martin D. Wilson dated August 28, 2000.
10.15<F**> Employment agreement for Thomas S. Hilton dated August 31, 2000.
10.16<F*> Employment Agreement for Vice President, General Counsel and
Secretary dated March 17, 1999, filed as an exhibit to the
registrant's Quarterly Report on Form 10-Q for the quarter ended
March 31, 1999.
10.17<F**> D&K Healthcare Resources, Inc. Executive Retirement Benefit Plan,
dated January 1, 1998.
13<F**> Registrant's 2000 Annual Report to Stockholders.
18<F**> Preferability letter by Arthur Andersen LLP
21<F**> Subsidiaries of the registrant.
23<F**> Consent of Arthur Andersen LLP.
27<F**> Financial data schedule.
<FN>
<F*> Incorporated by reference.
<F**> Filed herewith.
<F***> Incorporated by reference. Confidential portion omitted and filed
separately with the Commission.
</TABLE>
37
